These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27863924)

  • 1. Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.
    Jakubowski CD; Plodkowski AJ; Chang JC; Rekhtman N; Iqbal A; Paik PK; Yu HA
    Clin Lung Cancer; 2017 Jan; 18(1):e81-e83. PubMed ID: 27863924
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.
    Matsuoka H; Kaneda H; Sakai K; Koyama A; Nishio K; Nakagawa K
    Clin Lung Cancer; 2017 Jan; 18(1):e85-e87. PubMed ID: 28341110
    [No Abstract]   [Full Text] [Related]  

  • 3. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M; Okamoto I; Nakagawa K
    Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
    Nonagase Y; Okamoto K; Iwasa T; Yoshida T; Tanaka K; Takeda M; Kaneda H; Shimizu T; Tsurutani J; Nakagawa K
    Anticancer Drugs; 2016 Mar; 27(3):251-3. PubMed ID: 26575001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma.
    Bosch-Barrera J; Sais E; Lorencio C; Porta R; Izquierdo A; Menéndez JA; Brunet J; Sirvent JM; Rosell R
    Lung Cancer; 2014 Oct; 86(1):102-4. PubMed ID: 25097032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
    Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
    Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity].
    Tanaka H; Inomata M; Hayashi R; Shimokawa K; Tokui K; Okazawa S; Kambara K; Yamada T; Miwa T; Kashii T; Konishi H; Tobe K
    Gan To Kagaku Ryoho; 2017 Jul; 44(7):595-597. PubMed ID: 28790264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes.
    Fraser A
    N Z Med J; 2017 Mar; 130(1451):11-20. PubMed ID: 28253240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management Difficulties in a Patient with EGFR-mutation Positive Lung Adenocarcinoma and Cerebral Metastases.
    Cruz P; de Lujan L; de Castro J
    Arch Bronconeumol; 2017 Jan; 53(1):37-38. PubMed ID: 27712850
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries.
    Amin Z; Jayalie VF; Rajabto W
    Acta Med Indones; 2017 Jan; 49(1):79-88. PubMed ID: 28450659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.
    Lai YC; Lin PC; Lai JI; Hsu SY; Kuo LC; Chang SC; Wang WS
    Int J Clin Pharmacol Ther; 2011 Jul; 49(7):461-6. PubMed ID: 21726497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
    Ueda H; Hayashi H; Kudo K; Takeda M; Nakagawa K
    Invest New Drugs; 2016 Dec; 34(6):797-799. PubMed ID: 27550238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal thumbnail fissures due to erlotinib therapy for lung cancer.
    Dasanu CA; Alvarez-Argote J; Lippman SM; Plaxe SC
    J Oncol Pharm Pract; 2018 Apr; 24(3):229-231. PubMed ID: 28436313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.
    Yang JC; Shih JY; Su WC; Hsia TC; Tsai CM; Ou SH; Yu CJ; Chang GC; Ho CL; Sequist LV; Dudek AZ; Shahidi M; Cong XJ; Lorence RM; Yang PC; Miller VA
    Lancet Oncol; 2012 May; 13(5):539-48. PubMed ID: 22452895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Four cases of interstitial lung disease induced by erlotinib and a review of the literatures].
    Wu X; Gao G; Ren S; Zhou C
    Zhongguo Fei Ai Za Zhi; 2012 Aug; 15(8):494-8. PubMed ID: 22901999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib.
    Zhu YC; Du KQ; Wang WX; Song ZB; Xu CW; Chen G; Zhuang W; Lv TF; Song Y
    Lung Cancer; 2018 Jul; 121():101-104. PubMed ID: 29773459
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
    van der Wekken AJ; Kuiper JL; Saber A; Terpstra MM; Wei J; Hiltermann TJN; Thunnissen E; Heideman DAM; Timens W; Schuuring E; Kok K; Smit EF; van den Berg A; Groen HJM
    PLoS One; 2017; 12(8):e0182885. PubMed ID: 28854272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.